Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) was downgraded by investment analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research report issued on Monday. They currently have a $161.19 target price on the specialty pharmaceutical company’s stock. Vetr‘s target price points to a potential upside of 11.88% from the company’s current price.

Several other equities research analysts have also recently issued reports on the stock. Leerink Swann reissued an “outperform” rating on shares of Jazz Pharmaceuticals plc – in a research report on Monday. Cowen and Company restated a “positive” rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals plc – in a report on Monday. BMO Capital Markets restated a “positive” rating and issued a $192.00 price target on shares of Jazz Pharmaceuticals plc – in a report on Monday. Zacks Investment Research lowered shares of Jazz Pharmaceuticals plc – from a “hold” rating to a “sell” rating in a report on Thursday, March 2nd. Finally, Cantor Fitzgerald set a $187.00 price target on shares of Jazz Pharmaceuticals plc – and gave the company a “buy” rating in a report on Wednesday, March 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have given a buy rating to the company’s stock. Jazz Pharmaceuticals plc – has an average rating of “Buy” and an average price target of $178.32.

Analyst Recommendations for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 6.91% on Monday, reaching $144.08. 1,753,586 shares of the company’s stock traded hands. Jazz Pharmaceuticals plc – has a 52 week low of $95.80 and a 52 week high of $160.00. The firm has a market capitalization of $8.61 billion, a P/E ratio of 22.48 and a beta of 1.22. The stock has a 50-day moving average of $131.85 and a 200 day moving average of $119.55.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/jazz-pharmaceuticals-plc-jazz-lowered-to-buy-at-vetr-inc.html

Your IP Address:

In other news, COO Russell J. Cox sold 4,000 shares of Jazz Pharmaceuticals plc – stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $128.75, for a total transaction of $515,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Paul Treacy sold 884 shares of Jazz Pharmaceuticals plc – stock in a transaction on Monday, March 6th. The stock was sold at an average price of $131.97, for a total transaction of $116,661.48. Following the completion of the sale, the senior vice president now owns 18,108 shares of the company’s stock, valued at approximately $2,389,712.76. The disclosure for this sale can be found here. Insiders have sold 5,484 shares of company stock worth $709,335 in the last quarter. Insiders own 3.90% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Tourbillon Capital Partners L.P. raised its stake in shares of Jazz Pharmaceuticals plc – by 1,152.9% in the fourth quarter. Tourbillon Capital Partners L.P. now owns 826,882 shares of the specialty pharmaceutical company’s stock worth $90,155,000 after buying an additional 760,882 shares during the period. Herndon Capital Management LLC raised its stake in shares of Jazz Pharmaceuticals plc – by 231.3% in the fourth quarter. Herndon Capital Management LLC now owns 984,219 shares of the specialty pharmaceutical company’s stock worth $138,342,000 after buying an additional 687,100 shares during the period. Renaissance Technologies LLC raised its stake in shares of Jazz Pharmaceuticals plc – by 70.6% in the fourth quarter. Renaissance Technologies LLC now owns 1,560,300 shares of the specialty pharmaceutical company’s stock worth $170,120,000 after buying an additional 645,500 shares during the period. Norges Bank bought a new stake in shares of Jazz Pharmaceuticals plc – during the fourth quarter worth about $61,558,000. Finally, Cadian Capital Management LP raised its stake in shares of Jazz Pharmaceuticals plc – by 71.6% in the third quarter. Cadian Capital Management LP now owns 1,311,292 shares of the specialty pharmaceutical company’s stock worth $159,296,000 after buying an additional 547,056 shares during the period. Institutional investors and hedge funds own 88.56% of the company’s stock.

About Jazz Pharmaceuticals plc –

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

To view Vetr’s full report, visit Vetr’s official website.

Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with MarketBeat.com's FREE daily email newsletter.